Precision medicine launched tumor gene sequencing pilot

Source: China Securities Journal April 14, 2015 The state health and Family Planning Commission, medical administration and medical administration recently announced the list of the first batch of clinical application pilot units of tumor high-throughput gene sequencing Guangzhou Da'an clinical test center, a subsidiary of Da'an gene holding company, and Hangzhou Di'an medical test center, a wholly-owned subsidiary of Di'an diagnosis, were selected The Affiliated Tumor Hospital of Sun Yat sen University and Shenzhen Huada clinical test center were also among the first batch of pilot units The national health and Family Planning Commission pointed out that through the pilot, we will do a good job in the verification and evaluation of high-throughput gene sequencing technology, gradually improve the relevant technical specifications, and improve the application and management level of high-throughput gene sequencing technology in tumor diagnosis and treatment In fact, since the concept of precision medicine was put forward, China's response has been rapid On March 11, 2015, the Ministry of science and technology held the first national expert meeting on precision medicine strategy and proposed China's precision medicine plan for the first time Experts at the meeting suggested that the country put out a huge amount of funds to invest in this field The reporter learned that at present, relevant ministries and commissions are carrying out research and demonstration on the financing and investment direction of this fund Multinational governments attach importance to 3 At the end of the month, the state health and Family Planning Commission issued the notice on the application of pilot units for clinical application of high-throughput gene sequencing technology, stipulating that medical institutions that have already carried out high-throughput gene sequencing technology and meet the requirements for application can apply for pilot, and submit application materials to the provincial health and family planning administration according to the principle of territorial management, while clarifying Apply for pilot gene sequencing projects In less than two weeks, the first batch of five pilot units including Guangzhou Da'an clinical test center was released The first batch of clinical application pilot includes three specialties: genetic disease diagnosis, prenatal screening and diagnosis, and preimplantation embryo genetic diagnosis With the introduction of high-throughput sequencing technology and the improvement of "big data" processing capacity, modern medicine is undergoing tremendous changes, from the traditional standardized medical model to the precision medical model The completion of the human genome project and DNA encyclopedia project and the mapping of tumor gene map provide a powerful tool for the precision medicine of "measurement type medicine", and the medical field faces new opportunities Precision medicine is a customized medical model based on personal genomic information, combined with proteomics, metabonomics and other relevant internal environment information, to design a treatment plan for patients, in order to maximize the treatment effect and minimize the side effects Compared with traditional medicine, individualized medicine has the characteristics of pertinence, efficiency and prevention At the end of January 2015, President Barack Obama announced the launch of precision medical plan in his state of the Union address In early February, the White House website released details about the precision medical plan, which will speed up the understanding of diseases at the genomic level, and provide the latest and best technology, knowledge and treatment methods to clinicians, so that doctors can accurately understand the causes of diseases People familiar with the matter said that after the relevant national ministries and commissions learned about the precision medical plan of the United States, they soon reported the special document of the plan to the national senior level, who immediately instructed the Ministry of science and technology of the people's Republic of China to lead the research, and the Ministry of science and technology encouraged the Beijing Institute of genomics of the Chinese Academy of Sciences to conduct in-depth research in this field On March 11, the Ministry of science and technology took the lead in convening the first national expert meeting on precision medicine strategy and proposed China's precision medicine plan for the first time According to some analysis and prediction, China's precision medicine will invest 60 billion yuan by 2030, including 20 billion yuan from the central government and 40 billion yuan from enterprises and local governments As of the time of press release, the Ministry of science and technology has not responded to this In fact, the UK has the most sensitive sense of smell in the field of precision medicine In 2012, the UK government launched a large sequencing research project - "100000 genome project", which aims to sequence the complete genome of 100000 patients in the NHS Its goal is to develop personalized cancer and rare disease therapies based on genomics and clinical data, and make NHS "the first mainstream health service system in the world that will provide genomic medicine as part of daily care" So far, hundreds of genomes have been sequenced in the UK It is estimated that 10000 samples will be sequenced in 2016 and 100000 samples will be completed by 2017 The premise of personality, efficiency and prevention of big data analysis escort precision medicine lies in disease screening and diagnosis, so gene sequencing and big data application are the premise of the development of precision medicine From the perspective of the process of precision medicine, the industrial chain can be simply divided into two parts: diagnosis and treatment The diagnosis process mainly involves the application of molecular diagnosis technology, big data and cloud computing Through the collection and detection of a single patient's relevant samples, and comparison with the data of related diseases in the database, the relevant diagnosis results are obtained In the treatment stage, we can carry out the "measurement type drug" according to the diagnosis results Big data analysis will play a huge role in precision medicine Gene sequencing technology is the prerequisite for the implementation of precision treatment, and the data generated after gene sequencing depends on the comparative analysis of big data A fully sequenced human genome contains 100gb-1000gb of data, which is very difficult to interpret A special database is needed for horizontal and vertical comparison and analysis of data information Many foreign companies have established their own large databases and developed relevant software for rapid data analysis For example, Myriad Genetics company has a proprietary database for integrated analysis of big data, which can be used to explain uncertain genetic test results Illumina company has developed basespace's cloud computing and storage platform Sevenbridges genomics has integrated cloud computing and NoSQL data technology in human genome sequencing and analysis, and launched EC2, S3 and mongodb In the A-share market, rongzhilian, a listed company, by virtue of its accumulated technical advantages in high-performance computing and large capacity storage, designed, built and maintained the bioinformatics supercomputing centers in Shenzhen and Hong Kong for Huada gene, and successfully solved the problems in parallel computing and storage of massive data generated by gene sequencing At present, BGI has the supercomputing ability to run 157 trillion times per second, with data storage capacity of 12.6pb, and gene sequencing ability ranking first in the world The information obtained from big data comparison and analysis can provide guidance for individualized drug design and realize "drug measurement" At present, "drug genotyping" is the most practical application in many predictive gene testing projects The target drug was designed according to the human disease gene fragment, and the reactions, efficacy, sensitivity and side effects of the drug were analyzed with big data At the same time, the best treatment method and individualized drug delivery scheme were selected by using the patient's information and detection methods "Quantity and type of medicine" will greatly reduce the improper use of clinical drugs, improve the efficacy and reduce medical costs, and point out the direction for future medicine In the short term, personalized medical technologies and products have limited contribution to the income of related companies, but with the continuous development of the market, they will bring considerable incremental contribution to the income of related companies in the future At present, the national health and Family Planning Commission allows high-risk pregnant women who are more than 12 weeks pregnant to use gene sequencing technology for non-invasive prenatal screening Taking this test as an example, the number of newborns in China is about 16 million every year, and the market size is about 5.6 billion yuan / year based on a market penetration of 10% and a market volume of 3500 yuan / person time With the development of technology, the cost will continue to decline, which will further open up market space Assuming that the cost goes down to 1500 yuan / person time and the penetration rate reaches 50%, the market space is expected to go up to 12 billion yuan / year Considering the 34 million cancer patients every year, the application space of gene sequencing is more huge The results of the third sampling survey on the causes of death in 2006 showed that in the past 30 years, the death rate of breast cancer increased by 96%, and the death rate of lung cancer increased by 465% According to the statistics of the world cancer report, in 2012, the number of cancer cases in China was 3.065 million, accounting for about 1 / 5 of the global incidence; the number of cancer deaths was 2.25 million, accounting for about 1 / 4 of the global cancer deaths For the treatment of this kind of malignant diseases, on the one hand, we should increase the research and development of treatment drugs, on the other hand, we should make breakthroughs in treatment technology from the perspective of precision treatment Industry insiders said that the current cancer treatment is gradually changing from the macro level to the "disease" drug use to a more micro level of gene drug use, to achieve "different treatment of the same disease" or "different treatment of different diseases", precision treatment has become a recognized trend of cancer treatment In view of the broad market prospect of tumor gene sequencing, after several years of non-invasive prenatal sequencing battle, many domestic gene companies began to enter the tumor detection market and began to compete for this big cake Previously, only the Xiangya Medical Laboratory of Central South University, Beijing Bo'ao medical laboratory and the First Affiliated Hospital of China Medical University were approved by the national health and Family Planning Commission for individualized treatment of tumors, all of which are in the background of the government and have been carried out slowly With the development of the above pilot projects, some companies have started first Cancer detection is one of the "death" strategies in "life and death strategy" of Huada medicine The cancer package of Huada Medical Co., Ltd has been released recently and is being put into the market The target customers include not only healthy people and high-risk people, but also auxiliary treatment and prognosis monitoring This package is the most comprehensive in the Chinese market Healthy and high-risk groups are suitable for "genetic tumor screening", including 15 kinds of common tumors for men and 16 kinds of common tumors for women Breast cancer, ovarian cancer, lung cancer and other common cancers are all within the scope of the package Patients with tumors are suitable for individualized treatment package, which is positioned for targeted drugs, prognosis and recurrence monitoring, etc Business profile of listed companies related to gene sequencing Da'an gene in 2012, the company announced the joint venture with life technologies of the United States to establish Guangzhou lifeda'an diagnostic product technology Co., Ltd to start gene sequencing molecular diagnosis project It is understood that the gene sequencing platform of Da'an gene is directly facing the clinical customers of the hospital and more close to the market Qianshan Pharmaceutical Machinery Co., Ltd announced in March 2014 that it planned to acquire part of the equity of Hunan Honghao gene biology company and increase its capital Data shows that the main products of Honghao gene are gene chip, coronary heart disease gene detection chip and nervous system disease gene detection In October 2013, Zixin Pharmaceutical Co., Ltd plans to jointly develop the gene sequencer project with Beijing Institute of genomics, Chinese Academy of Sciences, which will enable the company's business to extend and expand to the field of disease early warning and detection of genes related to personalized drug use, as well as the field of high-end life science and medical analysis equipment Ma Yinglong holds 36.67% of the shares of Hubei Vinda Gene Technology Co., Ltd., which is mainly engaged in the research and development of gene detection technology and consulting services The company also holds 51.00% equity of Wuhan Mayinglong Daan Gene Diagnosis Technology Co., Ltd In August 2014, Beilu Pharmaceutical Co., Ltd increased its capital to Nanjing Shihe gene Biotechnology Co., Ltd by 30 million yuan, and subscribed for 20% of the increased capital